Roivant Sciences (ROIV) vs. The Competition Financial Survey

Roivant Sciences (NASDAQ:ROIV) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Roivant Sciences to related businesses based on the strength of its valuation, analyst recommendations, risk, institutional ownership, dividends, profitability and earnings.

Risk & Volatility

Roivant Sciences has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Roivant Sciences’ peers have a beta of 1.14, meaning that their average share price is 14% more volatile than the S&P 500.

Insider & Institutional Ownership

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 8.8% of Roivant Sciences shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Roivant Sciences and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Roivant Sciences Competitors	-12,359.35%	-203.09%	-30.93%

Analyst Recommendations

This is a breakdown of current ratings for Roivant Sciences and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1	2	10	1	2.79
Roivant Sciences Competitors	9801	15087	45415	1579	2.54

Roivant Sciences currently has a consensus price target of $46.55, indicating a potential upside of 20.77%. As a group, “Biotechnology” companies have a potential upside of 101.68%. Given Roivant Sciences’ peers higher possible upside, analysts plainly believe Roivant Sciences has less favorable growth aspects than its peers.

Valuation and Earnings

This table compares Roivant Sciences and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Roivant Sciences	$7.53 million	-$299.77 million	-72.72
Roivant Sciences Competitors	$736.67 million	$13.62 million	-14.85

Roivant Sciences’ peers have higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Roivant Sciences beats its peers on 8 of the 13 factors compared.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.